C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2026)
C4 Therapeutics' quarterly Free Cash Flow came in at -$30.0 million in Q1 2026, up 9.92% year-on-year from -$27.3 million in Q1 2025, and down 35.32% quarter-over-quarter from -$22.2 million in Q4 2025.
C4 Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$30.0 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 9.92% year-over-year to -$30.0 million; the trailing twelve-month figure through Mar 2026 stood at -$96.0 million (down 19.25% YoY), and the FY2025 full-year result was -$99.3 million, down 51.98% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$30.0 million, down from -$22.2 million in the prior quarter.
- The five-year high for Free Cash Flow was -$5.0 million in Q2 2024, with the low at -$33.3 million in Q1 2023.
- Average Free Cash Flow over 5 years is -$24.0 million, with a median of -$25.3 million recorded in 2022.
- Year-over-year, Free Cash Flow surged 73.79% in 2024 and sank 147.66% in 2025.
- Tracing CCCC's Free Cash Flow over 5 years: stood at -$28.1 million in 2022, then advanced by 20.14% to -$22.5 million in 2023, then climbed by 20.23% to -$17.9 million in 2024, then slipped by 23.58% to -$22.2 million in 2025, then tumbled by 35.32% to -$30.0 million in 2026.
- The last three Free Cash Flow figures came in at -$30.0 million (Q1 2026), -$22.2 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -29.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.98 Mn |
| Mar 31, 2026 | -29.98 Mn |
| Dec 31, 2025 | -22.16 Mn |
| Dec 31, 2025 | -22.16 Mn |
| Sep 30, 2025 | -31.51 Mn |
| Sep 30, 2025 | -31.51 Mn |
| Jun 30, 2025 | -12.35 Mn |
| Jun 30, 2025 | -12.35 Mn |
| Mar 31, 2025 | -33.29 Mn |
| Mar 31, 2025 | -33.29 Mn |
| Dec 31, 2024 | -17.93 Mn |
| Dec 31, 2024 | -17.93 Mn |
| Sep 30, 2024 | -24.30 Mn |
| Sep 30, 2024 | -24.30 Mn |
| Jun 30, 2024 | -4.99 Mn |
| Jun 30, 2024 | -4.99 Mn |
| Mar 31, 2024 | -18.12 Mn |
| Mar 31, 2024 | -18.12 Mn |
| Dec 31, 2023 | -22.48 Mn |
| Dec 31, 2023 | -22.48 Mn |
| Sep 30, 2023 | -32.04 Mn |
| Sep 30, 2023 | -32.04 Mn |
| Jun 30, 2023 | -19.02 Mn |
| Jun 30, 2023 | -19.02 Mn |
| Mar 31, 2023 | -33.32 Mn |
| Mar 31, 2023 | -33.32 Mn |
| Dec 31, 2022 | -28.15 Mn |
| Dec 31, 2022 | -28.15 Mn |
| Sep 30, 2022 | -26.21 Mn |
| Sep 30, 2022 | -26.21 Mn |
| Jun 30, 2022 | -25.29 Mn |
| Jun 30, 2022 | -25.29 Mn |
| Mar 31, 2022 | -26.77 Mn |
| Mar 31, 2022 | -26.77 Mn |
| Dec 31, 2021 | -25.78 Mn |
| Dec 31, 2021 | -25.78 Mn |
| Sep 30, 2021 | -18.36 Mn |
| Sep 30, 2021 | -18.36 Mn |
| Jun 30, 2021 | -18.75 Mn |
| Jun 30, 2021 | -18.75 Mn |
| Mar 31, 2021 | -25.36 Mn |
| Mar 31, 2021 | -25.36 Mn |
| Dec 31, 2020 | -22.23 Mn |
| Dec 31, 2020 | -22.23 Mn |
| Sep 30, 2020 | -14.33 Mn |
| Sep 30, 2020 | -14.33 Mn |
| Jun 30, 2020 | -14.66 Mn |
| Jun 30, 2020 | -14.66 Mn |
| Mar 31, 2020 | -16.68 Mn |
| Mar 31, 2020 | -16.68 Mn |
| Dec 31, 2019 | -11.56 Mn |
| Dec 31, 2019 | -11.56 Mn |